[New Treatment Options for Chronic Pruritus]

Overview

Journal Hautarzt

Specialty Dermatology

Date 2016 Jun 29

PMID 27351559

Authors

C Zeidler

B Pfleiderer

S Stander

Affiliations

Soon will be listed here.

Abstract

Prevalent in 14-17 % of the population, chronic pruritus is among the most common and stressful symptoms in medicine. In spite of new findings regarding the origin and chronification of the symptom, therapy remains a great challenge. There is a lack of approved therapies that provide rapid and efficient reduction of pruritus. As a result, the affected patients suffer a long time (even months to years), and somatic (scratch lesions, super infections, sleep disorders) and psychosomatic disorders develop. Interdisciplinary cooperation with various specialists is important not just for these reasons, but also due to different etiologies of the symptom and common comorbidities. In addition, there remains a great need for uniformly devised, clinically controlled studies, recommendations and guidelines. New therapeutic approaches are currently being verified in clinical trials. This allows for future prospects of possible new and partially targeted therapies. This article provides a summary of current therapeutic options based on case series, individual randomized controlled trials and the current S2K guideline.

References

Szeimies R, Stolz W, Wlotzke U, Korting H, Landthaler M . Successful treatment of hydroxyethyl starch-induced pruritus with topical capsaicin. Br J Dermatol. 1994; 131(3):380-2. DOI: 10.1111/j.1365-2133.1994.tb08529.x. View

Narbutt J, Olejniczak I, Sobolewska-Sztychny D, Sysa-Jedrzejowska A, Slowik-Kwiatkowska I, Hawro T . Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients. Arch Dermatol Res. 2012; 305(3):191-5. PMC: 3606511. DOI: 10.1007/s00403-012-1293-6. View

Hamilton J, Ungar B, Guttman-Yassky E . Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015; 7(10):1043-58. DOI: 10.2217/imt.15.69. View

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

Stander S, Bockenholt B, Schurmeyer-Horst F, Weishaupt C, Heuft G, Luger T . Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol. 2009; 89(1):45-51. DOI: 10.2340/00015555-0553. View

Stander S, Luger T, Metze D . Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol. 2001; 44(3):471-8. DOI: 10.1067/mjd.2001.110059. View

Ingber S, Cohen P . Successful treatment of refractory aquagenic pruritus with naltrexone. J Cutan Med Surg. 2006; 9(5):215-6. DOI: 10.1007/s10227-005-0144-x. View

Makhlough A, Ala S, Haj-Heydari Z, Kashi Z, Bari A . Topical capsaicin therapy for uremic pruritus in patients on hemodialysis. Iran J Kidney Dis. 2010; 4(2):137-40. View

Caterina M . Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am J Physiol Regul Integr Comp Physiol. 2006; 292(1):R64-76. DOI: 10.1152/ajpregu.00446.2006. View

10.

Stander S, Stumpf A, Osada N, Wilp S, Chatzigeorgakidis E, Pfleiderer B . Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol. 2013; 168(6):1273-80. DOI: 10.1111/bjd.12267. View

11.

Ko M, Peng Y, Chen H, Hsu S, Pai M, Yang J . Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol. 2014; 71(6):1151-1159.e1. DOI: 10.1016/j.jaad.2014.08.004. View

12.

Spring P, Gschwind I, Gilliet M . Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol. 2014; 39(4):468-73. DOI: 10.1111/ced.12365. View

13.

Phan N, Bernhard J, Luger T, Stander S . Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010; 63(4):680-8. DOI: 10.1016/j.jaad.2009.08.052. View

14.

Lee J, Girouard S, Carlberg V, Mostaghimi A . Effective use of mirtazapine for refractory pruritus associated with carcinoma en cuirasse. BMJ Support Palliat Care. 2014; 6(1):119-21. DOI: 10.1136/bmjspcare-2014-000790. View

15.

Brenaut E, Marcorelles P, Genestet S, Menard D, Misery L . Pruritus: an underrecognized symptom of small-fiber neuropathies. J Am Acad Dermatol. 2014; 72(2):328-32. DOI: 10.1016/j.jaad.2014.10.034. View

16.

Zuberbier T . Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses. J Eur Acad Dermatol Venereol. 2011; 26(1):9-18. DOI: 10.1111/j.1468-3083.2011.04185.x. View

17.

Bernstein J, Parish L, Rapaport M, ROSENBAUM M, Roenigk Jr H . Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol. 1986; 15(3):504-7. DOI: 10.1016/s0190-9622(86)70201-6. View

18.

Murota H, Kitaba S, Tani M, Wataya-Kaneda M, Azukizawa H, Tanemura A . Impact of sedative and non-sedative antihistamines on the impaired productivity and quality of life in patients with pruritic skin diseases. Allergol Int. 2010; 59(4):345-54. DOI: 10.2332/allergolint.10-OA-0182. View

19.

Mazza M, Guerriero G, Marano G, Janiri L, Bria P, Mazza S . Treatment of prurigo nodularis with pregabalin. J Clin Pharm Ther. 2012; 38(1):16-8. DOI: 10.1111/jcpt.12005. View

20.

Stumpf A, Stander S, Warlich B, Fritz F, Bruland P, Pfleiderer B . Relations between the characteristics and psychological comorbidities of chronic pruritus differ between men and women: women are more anxious than men. Br J Dermatol. 2014; 172(5):1323-8. DOI: 10.1111/bjd.13492. View